PPI-induced hypergastrinaemia and Barrett's mucosa: the fog thickens
- 1Department of Gastroenterology and Liver Diseases, St. Olavs Hospital HF, University Hospital of Trondheim, Trondheim, Norway
- 2Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
- Correspondence to Dr Helge Lyder Waldum, Department of Gastroenterology, St. Olavs Hospital, Prinsesse Kristinas gt 1, NO-7006 Trondheim, Norway;
We read with interest the study by Obszynska and co-workers1 on proton pump inhibitors (PPIs) and Barrett's oesophagus, and the accompanying editorial.2 The background for the study1 was whether PPIs are beneficial or harmful to patients with Barrett's oesophagus. They assessed the risks of PPI treatment by focusing on hypergastrinaemia, the presence of the cholecystokinin 2 (CCK2) receptor in different tissues by immunohistochemistry, and gene expression analysis. Furthermore, they analysed the effect of gastrin on cell lines transfected with the CCK2 receptor.
They found gastrin mRNA expression as expected in the antral mucosa, but also in the normal oesophageal mucosa as well as in Barrett's mucosa. Moreover, CCK2 mRNA expression was found not only in the oxyntic mucosa but also …